{"id":30743,"date":"2015-09-21T19:14:34","date_gmt":"2015-09-21T19:14:34","guid":{"rendered":"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/"},"modified":"2015-09-21T19:14:34","modified_gmt":"2015-09-21T19:14:34","slug":"brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients","status":"publish","type":"rss_externo","link":"https:\/\/www.clpu.es\/en\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/","title":{"rendered":"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients"},"content":{"rendered":"<p>Bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy, a new report suggests. While standard chemotherapy can achieve complete remissions in younger Hodgkin lymphoma patients, the majority of those 60 and older are either ineligible or refuse treatment in order to avoid complications related to drug toxicity.<br \/><a href='http:\/\/www.sciencedaily.com\/releases\/2015\/09\/150921151434.htm' title='Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients' target='_blank' rel=\"noopener\">http:\/\/www.sciencedaily.com\/releases\/2015\/09\/150921151434.htm<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"class_list":["post-30743","rss_externo","type-rss_externo","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients - CLPU<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients - CLPU\" \/>\n<meta property=\"og:description\" content=\"Bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy, a new report suggests. While standard chemotherapy can achieve complete remissions in younger Hodgkin lymphoma patients, the majority of those 60 and older are either ineligible or refuse treatment in order to avoid complications related to&hellip; Continue reading Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"CLPU\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.clpu.es\\\/rss_externo\\\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\\\/\",\"url\":\"https:\\\/\\\/www.clpu.es\\\/rss_externo\\\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\\\/\",\"name\":\"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients - CLPU\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.clpu.es\\\/#website\"},\"datePublished\":\"2015-09-21T19:14:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.clpu.es\\\/rss_externo\\\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.clpu.es\\\/rss_externo\\\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.clpu.es\\\/rss_externo\\\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.clpu.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RSS externos\",\"item\":\"https:\\\/\\\/www.clpu.es\\\/rss_externo\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.clpu.es\\\/#website\",\"url\":\"https:\\\/\\\/www.clpu.es\\\/\",\"name\":\"CLPU\",\"description\":\"Centro de L\u00e1seres Pulsados\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.clpu.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients - CLPU","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/","og_locale":"en_US","og_type":"article","og_title":"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients - CLPU","og_description":"Bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy, a new report suggests. While standard chemotherapy can achieve complete remissions in younger Hodgkin lymphoma patients, the majority of those 60 and older are either ineligible or refuse treatment in order to avoid complications related to&hellip; Continue reading Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients","og_url":"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/","og_site_name":"CLPU","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/","url":"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/","name":"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients - CLPU","isPartOf":{"@id":"https:\/\/www.clpu.es\/#website"},"datePublished":"2015-09-21T19:14:34+00:00","breadcrumb":{"@id":"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.clpu.es\/rss_externo\/brentuximab-vedotin-effective-safe-in-elderly-hodgkin-lymphoma-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.clpu.es\/en\/"},{"@type":"ListItem","position":2,"name":"RSS externos","item":"https:\/\/www.clpu.es\/rss_externo\/"},{"@type":"ListItem","position":3,"name":"Brentuximab vedotin effective, safe in elderly Hodgkin lymphoma patients"}]},{"@type":"WebSite","@id":"https:\/\/www.clpu.es\/#website","url":"https:\/\/www.clpu.es\/","name":"CLPU","description":"Centro de L\u00e1seres Pulsados","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.clpu.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.clpu.es\/en\/wp-json\/wp\/v2\/rss_externo\/30743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.clpu.es\/en\/wp-json\/wp\/v2\/rss_externo"}],"about":[{"href":"https:\/\/www.clpu.es\/en\/wp-json\/wp\/v2\/types\/rss_externo"}],"author":[{"embeddable":true,"href":"https:\/\/www.clpu.es\/en\/wp-json\/wp\/v2\/users\/2"}],"wp:attachment":[{"href":"https:\/\/www.clpu.es\/en\/wp-json\/wp\/v2\/media?parent=30743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}